Patent · US Expired

Imidazotriazines for use as phosphodiesterase inhibitors

US6936609B2 · kind B2 · utility

10Cited by

1References

7Claims

0Family size

Assignee

BAYER HEALTHCARE LLC · DE

Inventors

Ulrich Niewohner · Wermelskirchen, DE
Marcus Bauser · Berlin, DE
Nils Burkhardt · Velbert, DE
Dietmar Flubacher · Glückstadt, DE
Arno Friedl · Bensberg, DE
Irene Gerlach · Cologne, DE
Volker Hinz · Cologne, DE
Reinhard Jork · Haan, DE
Paul Naab · Bad Reichenhall, DE
Thorsten-Oliver Repp · Wesseling, DE
Karl-Heinz Schlemmer · Wuppertal, DE
Jurgen Stoltefuss · Haan, DE
David Bruckner · Essen, DE
Martin Hendrix · Tarrytown, US
Dagmar Schauss · Wuppertal, DE
Adrian Tersteegen · Wuppertal, DE
Jens-Kerim Ergden · Wülfrath, DE

Key dates

Filing date	Jun 10, 2002
Grant date	Aug 30, 2005
Priority date	—
Expiry date	Jul 2, 2022

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.